Nabriva Therapeutics (NASDAQ:NBRV) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a report issued on Wednesday, April 4th.
According to Zacks, “Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics’ medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics’ lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). “
A number of other research firms also recently commented on NBRV. ValuEngine downgraded Nabriva Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Morgan Stanley assumed coverage on Nabriva Therapeutics in a research report on Wednesday, January 17th. They set an “overweight” rating and a $10.00 price target on the stock. Cantor Fitzgerald set a $16.00 price target on Nabriva Therapeutics and gave the stock a “buy” rating in a research report on Friday, March 16th. Bank of America assumed coverage on Nabriva Therapeutics in a research report on Wednesday, March 21st. They set a “buy” rating and a $10.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating on shares of Nabriva Therapeutics in a research report on Monday, March 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $16.69.
Nabriva Therapeutics (NASDAQ:NBRV) last released its earnings results on Friday, March 16th. The biotechnology company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.06). Nabriva Therapeutics had a negative return on equity of 88.66% and a negative net margin of 1,370.53%. The firm had revenue of $1.12 million for the quarter, compared to the consensus estimate of $1.37 million. sell-side analysts expect that Nabriva Therapeutics will post -2.18 earnings per share for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC acquired a new stake in Nabriva Therapeutics in the 4th quarter valued at approximately $5,188,000. Alyeska Investment Group L.P. acquired a new stake in Nabriva Therapeutics in the 3rd quarter valued at approximately $5,724,000. Prosight Management LP acquired a new stake in Nabriva Therapeutics in the 4th quarter valued at approximately $2,939,000. Pura Vida Investments LLC acquired a new stake in Nabriva Therapeutics in the 3rd quarter valued at approximately $3,481,000. Finally, Rubric Capital Management LP acquired a new stake in Nabriva Therapeutics in the 3rd quarter valued at approximately $2,457,000. Hedge funds and other institutional investors own 55.56% of the company’s stock.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which has completed a Phase II clinical trial for acute bacterial skin and skin structure infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.